VIA
ABBV icon

Vident Investment Advisory’s AbbVie ABBV Stock Holding History

Vident Investment Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-192,442
Closed -$25.9M – 5
2023
Q2 		$25.9M Buy
192,442
+15,369
+9% +$2.25M 0.89% 9
2023
Q1 		$28.2M Buy
177,073
+30,837
+21% +$4.71M 0.92% 8
2022
Q4 		$23.6M Buy
146,236
+12,710
+10% +$1.95M 0.89% 13
2022
Q3 		$16.8M Sell
133,526
-1,024
-0.8% -$147K 0.55% 32
2022
Q2 		$20.6M Sell
134,550
-18,400
-12% -$2.81M 0.62% 21
2022
Q1 		$24.8M Sell
152,950
-9,246
-6% -$1.34M 0.65% 22
2021
Q4 		$22M Buy
162,196
+44,486
+38% +$5.25M 0.57% 40
2021
Q3 		$12.7M Buy
117,710
+15,830
+16% +$1.81M 0.38% 61
2021
Q2 		$11.5M Buy
101,880
+77,612
+320% +$8.74M 0.35% 59
2021
Q1 		$2.63M Sell
24,268
-16,861
-41% -$1.8M 0.09% 254
2020
Q4 		$4.41M Sell
41,129
-37,582
-48% -$3.61M 0.18% 99
2020
Q3 		$6.89M Buy
78,711
+1,699
+2% +$160K 0.34% 63
2020
Q2 		$7.56M Buy
77,012
+29,865
+63% +$2.63M 0.4% 56
2020
Q1 		$3.59M Buy
47,147
+24,551
+109% +$2.09M 0.24% 80
2019
Q4 		$2M Buy
22,596
+87
+0.4% +$7.22K 0.12% 257
2019
Q3 		$1.7M Sell
22,509
-3,295
-13% -$226K 0.15% 98
2019
Q2 		$1.88M Buy
25,804
+5,257
+26% +$413K 0.15% 92
2019
Q1 		$1.66M Buy
20,547
+397
+2% +$32.5K 0.09% 319
2018
Q4 		$1.86M Buy
20,150
+3,058
+18% +$269K 0.1% 270
2018
Q3 		$1.62M Buy
17,092
+329
+2% +$31.2K 0.06% 371
2018
Q2 		$1.55M Buy
16,763
+3,698
+28% +$361K 0.06% 354
2018
Q1 		$1.21M Sell
13,065
-4,970
-28% -$546K 0.05% 363
2017
Q4 		$1.74M Buy
18,035
+4,341
+32% +$409K 0.08% 297
2017
Q3 		$1.22M Buy
+13,694
New +$1.04M 0.07% 342
2015
Q4 		– Sell
-56
Closed -$3K – 367
2015
Q3 		$3K Sell
56
-438
-89% -$28.5K ﹤0.01% 951
2015
Q2 		$33K Buy
+494
New +$32.3K ﹤0.01% 810
2015
Q1 		– Sell
-12,969
Closed -$849K – 679
2014
Q4 		$849K Buy
+12,969
New +$818K 0.29% 71

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vident Investment Advisory's ABBV Position: Q3 2023 in Review

Vident Investment Advisory sold out of AbbVie (ABBV) in Q3 2023, closing a stake of 192,442 shares — an estimated $25.9M sold.

Vident Investment Advisory first reported a position in ABBV in Q4 2014 and held it in 27 quarters. The position peaked at $28.2M in Q1 2023. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

  • Vident Investment Advisory reported no remaining AbbVie position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 192,442 AbbVie shares in Q3 2023, an estimated $25.9M.
  • Vident Investment Advisory first reported a position in AbbVie in Q4 2014 and held it in 27 quarters.
  • Vident Investment Advisory's AbbVie position peaked at $28.2M in Q1 2023.
  • 3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.